Status:
COMPLETED
The Healthcare Evaluation of Absolute Risk Testing Study
Lead Sponsor:
Genomics PLC
Collaborating Sponsors:
NHS North of England Commissioning Support (NECS)
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
45-64 years
Phase:
NA
Brief Summary
The aim of this study is to demonstrate the integration and use of cardiovascular disease (CVD) integrated risk tool (IRT) in an environment as close to real-world as possible. This study will recrui...
Detailed Description
The aim of this study is to demonstrate the integration and use of a cardiovascular disease (CVD) integrated risk tool (IRT) in an environment as close to real-world as possible. In association with ...
Eligibility Criteria
Inclusion
- Able and willing to provide written informed consent and to comply with the study protocol
- Either male or female (biological sex)
- Aged 45-64 years (inclusive)
- Any ancestry or background
- Eligible for NHS Health Check using QRISK®2 assessment
Exclusion
- Those excluded from NHS Health Checks;
- Currently prescribed and taking HMG-CoA reductase inhibitors (lipid-lowering preventive treatments or statins) for any indication.
Key Trial Info
Start Date :
November 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
862 Patients enrolled
Trial Details
Trial ID
NCT05294419
Start Date
November 4 2021
End Date
September 30 2022
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carmel Medical Practice
Darlington, Co Durham, United Kingdom, DL3 8SQ